Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition

JAAD Case Rep. 2019 Apr 20;5(5):401-405. doi: 10.1016/j.jdcr.2018.03.005. eCollection 2019 May.
No abstract available

Keywords: CLL, chronic lymphocytic leukemia; FCR, fludarabine, cyclophosphamide, rituximab; PI3K, phosphoinositide 3-kinase; cutaneous toxicity; immunotherapy; mTOR, mechanistic target of rapamycin; phosphoinositide 3-kinase inhibitors; psoriasis; small molecule inhibitors.

Publication types

  • Case Reports